Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001104659-25-122044
Filing Date
2025-12-17
Accepted
2025-12-17 16:10:48
Documents
15
Effectiveness Date
2025-12-17

Document Format Files

Seq Description Document Type Size
1 FORM S-8 tm2533221d1_s8.htm S-8 57526
2 EXHIBIT 5.1 tm2533221d1_ex5-1.htm EX-5.1 63646
3 EXHIBIT 23.1 tm2533221d1_ex23-1.htm EX-23.1 1962
4 EX-FILING FEES tm2533221d1_ex-filingfees.htm   iXBRL EX-FILING FEES 16295
5 GRAPHIC tm2533221d1_ex5-1img001.jpg GRAPHIC 7352
  Complete submission text file 0001104659-25-122044.txt   270115

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2533221d1_ex-filingfees_htm.xml XML 4882
Mailing Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE GHENT Belgium
Business Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE GHENT Belgium 32 (9) 310 34 00
ARGENX SE (Filer) CIK: 0001697862 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-292200 | Film No.: 251579389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)